Endpoint Health and Grifols Collaborate to Develop Antithrombin III for Sepsis
By Ayush Saxena & Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)
Published: 16 Mar-2022
DOI: 10.3833/pdr.v2022.i3.2677 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Endpoint Health and Grifols have entered into a global licensing and collaboration agreement to develop and commercialisean Antithrombin III therapy for the treatment of sepsis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS